Cream formulation with amphotericin B and oil in water useful for topical application to mucous tissue and skin against diseases produced by leishmaniasis
The cream formulation of the present invention is a topical cream made with antimycotic (amphotericin B) and a mixture of excipients where the water present in the formulation smoothes inflamed tissue. The cream has a particular application for the treatment of cutaneous leishmaniasis and mucosal leishmaniasis in humans and animals. The topical application avoids the risks of toxicity and the gastrointestinal hassles of pills treatments. It has greater acceptability from patient and does not require of valuations before, during or after treatment to check toxicity levels of the liver, kidney and heart.
1. A cream formulation for topical application to a patient's mucous tissue and/or skin against diseases produced by leishmaniasis, said formulation consisting of:
Amphotericin B as a pharmaceutical active ingredient from 0.3% to 3.0% by weight;
sodium methylparaben in 0.10% by weight;
sodium propylparaben in 0.02% by weight;
monobasic sodium phosphate in 0.96% by weight;
cetyl alcohol in 5.0% by weight;
light mineral oil in 4.0% by weight;
mixture of: Cetyl alcohol, Glyceryl Stearate, PEG-75 Stearate, Ceteth-20 and Steareth-20 in 2.90% by weight;
white petrolatum in 10.0% by weight;
glycerol monostearate in 0.7% by weight; and
water from 76.02% to 73.32% by weight.
2. The cream formulation according to claim 1 , wherein said cream formulation is applied for 15 days.
3. The cream formulation according to claim 1 , wherein said cream formulation has a 62.5% healing rate.
4. The cream formulation according to claim 1 , wherein said cream formulation has a 75% healing rate.
5. The cream formulation of claim 1 , wherein said formulation is administered topically to at least one of: mucous tissue and skin.
6. The cream formulation according to claim 1 , wherein said cream formulation is topically administered to a patient's mucous tissue or skin once a day.
7. The cream formulation according to claim 1 , wherein said cream formulation is topically administered to a patient's mucous tissue or skin twice a day.
8. The cream formulation according to claim 1 , wherein said cream formulation is applied for 15 days.